Race Oncology highlights impressive bisantrene clinical data

(via NewsDirect)

Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith discusses with Proactive impressive Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory acute myeloid leukaemia patients. Administered over four days, the drug combination induced a clinical response in 40% of evaluable patients with five patients receiving a potentially curative stem cell transplant.

“To see such meaningful clinical responses in a group that would typically be receiving palliative care is striking," said Smith.

"It is also encouraging that the safety profile was manageable, even for this advanced patient population.

"These are highly positive outcomes in a heavily pretreated patient population.”

Contact Details

Proactive Investors

Gregg Castano

[phone]

[e-mail]

Copyright (c) 2023 TheNewswire - All rights reserved.

Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases